Patients receiving high-dose methotrexate (HDMTX) for malignancies are exposed to
diverse complications, including nephrotoxicity, hepatotoxicity, mucositis, myelotoxicity …

Background Delayed methotrexate elimination can occur in patients undergoing high‐dose
methotrexate cancer treatment. Effectiveness of glucarpidase for rapidly reducing …

Abstract Study Objective Methotrexate (MTX) is a key component of treatment for high‐risk
pediatric acute lymphoblastic leukemia (ALL) but may cause acute kidney injury and …

Background High‐dose methotrexate (HD‐MTX; 5000 mg/m2) is an important component of
curative therapy in many treatment regimens for high‐risk pediatric acute lymphoblastic …

Methotrexate is a major component of pediatric leukemia treatment. While toxicities are
common after high-dose methotrexate, escalating dose methotrexate (Capizzi methotrexate) …

High‐dose methotrexate (HD‐MTX) infusions are commonly used to consolidate remission
in children with acute lymphoblastic leukemia (ALL). We investigate the potential role of …

Introduction Disparities in relapse and survival from high‐risk neuroblastoma (HRNBL)
persist among children from historically marginalized groups even in highly standardized …

Background Methotrexate is an important component of curative therapy in childhood acute
lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate …

Improved treatment strategies for childhood ALL over the past decades have resulted in
dramatically increased survival rates now exceeding 90%. However, antileukemic treatment …